title: [Therapeutic agents for disorders of bone and calcium metabolism: Weekly subcutaneous injection of teriparatide.].
abstract: Daily subcutaneous injection of parathyroid hormone (1-34) (teriparatide; TPTD), which is widely used regimen for osteoporotic patients in many countries, exerts strong action on increment of bone volume and prevention of fracture, but activated osteoclastic bone resorption might also occur in this regimen. In contrast, once weekly subcutaneous injection of TPTD, which is being developed in Japan, efficiently increase bone mass by stimulating bone formation without apparent bone resorption. Recent study demonstrated that weekly injection of TPTD increase bone strength in primates by improving bone mass, bone structure and bone quality. In addition, the weekly injection of TPTD increase lumber spine bone mineral density in osteoporotic patients as well as the daily injection. These data suggest that the weekly injection of TPTD is a useful regimen, which discriminate from the daily injection of TPTD.
authors.affiliation: Laboratory for Pharmacology, Pharmaceuticals Research Center, AsahiKasei Pharma Corporation.
authors.forename: Toshinori
authors.initials: T
authors.lastname: Ishizuya
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects; D004334:Drug Administration Schedule; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007279:Injections, Subcutaneous; D008159:Lumbar Vertebrae / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism; D013268:Stimulation, Chemical; D019379:Teriparatide / Q000008:administration & dosage* / Q000494:pharmacology; D013997:Time Factors
chemical_list: D019379:Teriparatide